Inhalation Devices in COPD - Full Details (15 Marks Answer)

Introduction

Classification of Inhalation Devices

1. Pressurized Metered-Dose Inhaler (pMDI)

Mechanism

• Drug is formulated as a liquid suspension or solution with a propellant inside a sealed pressurized canister.
• Older propellant: Chlorofluorocarbons (CFC/Freon) - now replaced by ozone-friendly Hydrofluoroalkanes (HFA) / Hydrofluorocarbons (HFC).
• On actuation, rapid vaporization of propellant aerosolizes the drug into fine particles.
• Typically delivers 50-200 doses per canister.

Particle Size and Lung Deposition

• Optimal particle size for lower airway deposition: 1-5 micrometers (MMAD)
• HFA pMDIs deliver finer particles to smaller airways but also increase systemic absorption.
• With standard technique: only ~10-20% of the dose reaches the lungs.

Correct Inhalation Technique (Critical for Exams)

1. Shake the inhaler
2. Exhale fully
3. Place mouthpiece in mouth and form a tight seal
4. Actuate at the START of a deep, slow inhalation lasting ~5 seconds
5. Hold breath for at least 5 seconds at end of inspiration
6. Wait 1 minute before second puff if needed

• Common errors: failure to inhale slowly and deeply; poor hand-mouth coordination (especially in elderly).

Breath-Actuated pMDI

• Triggered by patient's inspiratory flow to overcome coordination problems.
• Examples: Autohaler, Easi-Breathe.
• However, studies show no advantage over correct conventional pMDI technique.

Advantages

• Compact and portable
• Multidose (50-200 doses)
• Quick treatment time
• Drug in sealed canister (protected from humidity)
• Inexpensive

Disadvantages

• High oropharyngeal deposition (up to 80-90% without spacer)
• Requires good hand-mouth coordination
• Propellants may cause "cold Freon" effect
• HFA propellants contribute to climate change (carbon footprint)
• Difficult to assess when canister is empty

2. Spacer Devices (Valved Holding Chambers)

Mechanism

• A spacer is an add-on chamber placed between the pMDI and the patient's mouth.
• Reduces the high velocity of aerosol cloud.
• Allows evaporation of liquid propellant, producing smaller drug particles that deposit deeper in the lungs.
• Traps large particles on the plastic walls, reducing oropharyngeal impaction.

Types of Spacers

Clinical Importance in COPD

• Reduces oropharyngeal deposition of inhaled corticosteroids (ICS) - thus reducing local side effects (oral candidiasis, dysphonia) and systemic absorption via GI tract.
• Useful in elderly patients and children as young as 3 years with face mask attachment.
• Particularly helpful in patients with poor coordination.

Key Points for Correct Spacer Use

• Prime the spacer with the pMDI before use.
• Actuate one puff at a time - not multiple simultaneous doses (reduces electrostatic charge effect).
• Wash with ionic detergent and air dry to reduce electrostatic charge.
• Should be prescribed with compatible pMDI only - not interchangeable between devices.
• Antistatic spacers are available.

Advantages

• Overcomes coordination problems
• Reduces oropharyngeal deposition
• Reduces local and systemic ICS side effects
• Useful for elderly, children, and acute exacerbations

Disadvantages

• Bulky and less portable
• Electrostatic charge can reduce drug delivery
• Must be device-specific (not universally compatible)

3. Dry Powder Inhaler (DPI)

Mechanism

• Propellant-free devices.
• Drug is present as finely milled powder particles either:
  • Bound to larger lactose carrier molecules
  • As loose powder aggregates
• Breath-actuated: patient's own inspiratory effort disperses and de-aggregates the drug from the carrier particle.
• Requires minimum inspiratory flow rate for adequate drug dispersion (usually >30-60 L/min).

Classification of DPIs

DPI Devices Used in COPD (Examples)

• Turbuhaler - Budesonide, formoterol
• Accuhaler (Diskus) - Salmeterol/fluticasone, tiotropium
• Handihaler - Tiotropium (single-capsule device)
• Breezhaler - Indacaterol, glycopyrronium
• Genuair/Pressair - Aclidinium
• Ellipta - Umeclidinium/vilanterol, fluticasone furoate

Problems in COPD Patients

• Patients with moderate-to-severe COPD may not generate adequate inspiratory flows.
• Insufficient inspiratory effort is the most common inhaler error with DPIs - associated with worsening disease and increased exacerbation frequency.
• Children under 7 years cannot use DPIs effectively.
• Humidity can degrade the powder - must be stored in dry environment.

Advantages

• Compact and portable
• Quick treatment time
• Breath-actuated - no hand-mouth coordination needed
• No propellant (no ozone/climate issue)
• Simple to use if adequate inspiratory flow can be generated

Disadvantages

• Requires adequate inspiratory flow (problematic in severe COPD)
• High oropharyngeal deposition
• Humidity degrades the drug
• Patients may be intolerant to lactose carrier (rare)
• Not suitable for very young children or acutely ill patients with very poor inspiratory effort

4. Nebulizers

Mechanism

• Drug is dissolved or suspended in liquid (saline-based) and aerosolized into a fine mist for tidal breathing inhalation.
• Does NOT require coordination or high inspiratory effort.
• Suitable for tidal breathing at rest.
• Can deliver much higher drug doses than pMDIs.

Types of Nebulizers

A. Jet Nebulizer

• Uses compressed gas (air or oxygen) or an electrical compressor.
• High-velocity air directed through a Venturi opening across the liquid drug to produce aerosolized droplets.
• Most widely used type.
• Larger, noisier.
• Effective for both solutions and suspensions.

B. Ultrasonic Nebulizer

• Uses a rapidly vibrating piezoelectric crystal at high frequency to produce aerosol.
• Does NOT require a compressed gas source.
• Smaller and quieter than jet nebulizers.
• More expensive and less robust.
• Less effective for nebulizing suspensions.

C. Mesh Nebulizer (newer generation)

• Drug passes through a vibrating mesh with thousands of laser-drilled holes.
• More efficient drug delivery, less waste during exhalation.
• Better portability and consistency.
• Provides feedback for compliance monitoring.
• More expensive but cost-effective due to reduced drug waste.

Clinical Use in COPD

• Acute exacerbations of COPD - most common use, especially in hospital.
• When airway obstruction is extreme (severe COPD, inability to use other devices).
• Patients who are very old, very young, or mentally incapacitated.
• Delivery of high-dose antibiotics (e.g., inhaled tobramycin in bronchiectasis/COPD overlap).
• Drugs that must be given at high doses.

Factors Affecting Nebulizer Delivery

• Crying in children greatly reduces lung deposition.
• Shallow/rapid breathing reduces efficiency.
• Face mask must fit correctly to avoid drug deposition on the face and eyes.
• Significant variability in output between different nebulizer models.

Advantages

• Large doses of drug can be delivered
• Tidal breathing - no coordination or inspiratory effort needed
• Suitable for all ages including very young, elderly, acutely ill
• Many drug solutions can be aerosolized
• No patient cooperation needed for technique

Disadvantages

• Bulky, cumbersome, and expensive
• Wasted drug in nebulizer reservoir (significant loss during exhalation with conventional nebulizers)
• Variable aerosol output between models
• Time consuming (5-15 minutes per treatment)
• Requires power source
• Requires regular cleaning and maintenance (infection risk)

5. Soft Mist Inhaler (SMI) - e.g., Respimat

• Uses a spring-driven mechanical system to produce a slow-moving fine aerosol mist without propellant.
• More drug reaches the lungs (~50%) compared to pMDI (~10-20%).
• Slow aerosol velocity reduces oropharyngeal impaction.
• The combination of albuterol + ipratropium is available in SMI form.
• Useful in patients who struggle with pMDI coordination.
• Does not require strong inspiratory effort like DPIs.

Comparison Table: Advantages and Disadvantages

Factors Determining Choice of Inhaler in COPD

1. Disease severity - Severe COPD patients may not achieve adequate inspiratory flow for DPIs; nebulizers may be preferred.
2. Patient ability - Poor coordination favors DPIs, SMI, or spacer+pMDI; very old/young patients may need nebulizers.
3. Setting - Acute exacerbation: nebulizer preferred; stable outpatient: pMDI or DPI.
4. Drug availability - Not all drugs are available in all devices.
5. Cost - pMDI generally cheapest; mesh nebulizers most expensive.
6. Compliance - Same device type for all drugs improves compliance.
7. Technique training - Healthcare workers must assess and regularly review inhaler technique.
8. Environmental considerations - pMDI propellants (HFAs) contribute to climate change.

Key Exam Points

• DPIs are breath-actuated - require adequate inspiratory flow; problematic in severe COPD.
• pMDIs need hand-mouth coordination - solved by spacers or breath-actuated pMDIs.
• Nebulizers are gold standard in acute exacerbations and extreme airway obstruction.
• Spacers reduce ICS side effects (oral candidiasis, dysphonia, systemic absorption).
• Studies show pMDI, DPI, and SMI are equally effective as nebulizers in stable COPD patients who use correct technique.
• GOLD guidelines emphasize periodic reassessment of inhaler technique - incorrect technique is universal and worsens outcomes.
• More than 250 device-drug combinations exist; prescribers and patients are commonly confused.
• A newer generation of DPIs requires lower inspiratory flows or delivers drug independent of breathing maneuver.